COVID-19血栓并发症管理:最新进展
本文综述了COVID-19相关凝血病的病理生理、诊断和治疗的最新证据。建议所有COVID-19住院患者接受预防性抗凝,血栓栓塞事件风险较高或已发生静脉血栓栓塞者应接受治疗性抗凝。还讨论了高风险患者出院后预防及改善高凝状态的新兴治疗。
要点
- 所有COVID-19住院患者推荐预防性抗凝。
- 血栓栓塞风险高或已发生静脉血栓栓塞者应治疗性抗凝。
- 需关注高风险患者出院后预防及新兴高凝治疗。
核心结论
- COVID-19相关凝血病显著增加静脉血栓栓塞风险,抗凝管理是关键。
- 预防性抗凝适用于所有COVID-19住院患者。
- 治疗性抗凝适用于血栓栓塞风险较高或已发生静脉血栓栓塞的患者。
研究设计与样本
- 本文为综述,讨论COVID-19凝血病的病理生理、诊断和治疗的最新证据。
主要发现
- COVID-19以系统性炎症为主要机制,凝血病是其临床显著效应。
- 重症COVID-19患者血栓并发症发生率较高。
关键数值与推荐
- 所有COVID-19住院患者推荐预防性抗凝。
- 血栓栓塞事件风险较高或已发生静脉血栓栓塞者应接受治疗性抗凝。
临床怎么用
- 对COVID-19住院患者评估血栓风险并启动预防性抗凝。
- 对高风险或已发生静脉血栓栓塞者使用治疗性抗凝。
- 考虑高风险患者出院后预防及新兴高凝治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2), is now a global pandemic. This virus primarily affects the respiratory tract and causes lung injury characterized by acute respiratory distress syndrome. Although the pathophysiology of COVID-19 is not yet clear, the most widely accepted mechanism is systemic inflammation. A clinically significant effect of the inflammation is coagulopathy. As a result of this effect, patients are found to have a high risk of venous thromboembolism. Studies have reported a high incidence of thrombotic complications in critically ill patients with COVID-19. In this review, we discuss the most updated evidence on the pathophysiology, diagnosis, and treatment of the coagulopathy of COVID-19. Prophylactic anticoagulation is recommended for all in-patients with COVID-19. Those with a higher risk of developing thromboembolic events or who have already developed venous thromboembolism should be treated with therapeutic anticoagulation. We also discuss post-discharge prophylaxis for high-risk patients and some newly proposed treatments for the hypercoagulability that could improve the outcomes of the affected patients.
引用
- Hajra A, Mathai SV, Ball S, et al. Management of Thrombotic Complications in COVID-19: An Update. Drugs. 2020. PMID: 32803670. doi:10.1007/s40265-020-01377-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。